Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$3.04 USD
+0.27 (9.75%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $3.10 +0.06 (1.97%) 7:28 PM ET
5-Strong Sell of 5 5
F Value F Growth C Momentum F VGM
Brokerage Reports
Aquestive Therapeutics, Inc. [AQST]
Reports for Purchase
Showing records 41 - 60 ( 402 total )
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
2023 Outlook - New Commercial Launches, Clinical Catalysts & M&A Driving Value
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
EOP2 Minutes Sets the Stage for Pivotal PK Study for AQST-109 in 2023
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
EoP2 Meeting For AQST-109 in Q4; Libervant Updates; Q3 Financials
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Weekly Symphony Health Estimates for SYMPAZAN
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Positive AQST-109 EPIPHAST II Top-Line Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Topline Results from EPIPHAST II for AQST-109/Anaphylaxis; EoPh2 Meeting in Q4
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Weekly Symphony Health Estimates for SYMPAZAN
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Libervant Receives Tentative FDA Approval; Lowering PT to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
FDA Grants Libervant Tentative Approval; Focus Remains on AQST-109
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L